Multi-Omic Aging: Proteomics, Metabolomics and Beyond Epigenetics
Methylation is one layer of many. Proteomic and metabolomic clocks add something epigenetic clocks cannot: which organ is ageing faster than the rest.
The Short Answer
Epigenetic clocks read one molecular layer and return one number for the whole person. The layers above them, the proteins circulating in plasma and the metabolites they act on, carry different information, and the most interesting finding to come out of them is that ageing is not uniform across the body. Organ-specific proteomic clocks show that a person can have a heart ageing considerably faster than their brain, and that the fast-ageing organ predicts which condition arrives first.
The Layers and What Each Reads
| Layer | What it measures | Time constant |
|---|---|---|
| Genomic | Inherited sequence | Fixed |
| Epigenomic | Methylation and chromatin state | Months to years |
| Transcriptomic | Which genes are being read now | Hours to days |
| Proteomic | Circulating protein abundance | Days to weeks |
| Metabolomic | Small-molecule intermediates | Minutes to hours |
| Microbiomic | Gut community composition | Days to months |
The differing time constants are the point. Methylation is slow and stable, good for a cumulative reading and poor at reflecting this month. Metabolites are fast and volatile, sensitive to last night's meal and this morning's stress, which makes them poor for a stable estimate and good for state. Proteins sit usefully between the two.
Any single-layer clock is therefore answering a question shaped by its time constant, which is one reason different clocks disagree about the same person.
Organ-Specific Proteomic Ageing
Large plasma proteomic panels can now measure thousands of proteins from a single sample. Because many proteins are produced predominantly by one tissue, their abundance can be grouped by organ of origin, and each group modelled separately against age.
Work from Stanford and others has produced organ-specific age estimates for brain, heart, liver, kidney, lung, immune system, muscle, pancreas, intestine, vasculature and adipose tissue. The findings that follow are the substantive ones.
Ageing is asynchronous. Most people have at least one organ ageing notably faster than the rest, and which organ varies between individuals.
The fast organ is predictive. Accelerated heart age associates with subsequent cardiovascular events, accelerated brain age with cognitive decline and neurodegenerative conditions, accelerated kidney age with renal outcomes. The specificity is what a single whole-body number cannot provide.
Extreme agers exist. A minority show accelerated ageing across many organs simultaneously, and mortality risk in that group is substantially elevated.
This is the most genuinely actionable direction in biological age measurement, because a result that says which system is drifting connects to a specific set of interventions rather than to a general exhortation.
Metabolomic and Inflammatory Signatures
Metabolomic clocks read hundreds of small molecules, and the ageing signature is dominated by lipid species, amino acid derivatives and markers of mitochondrial substrate handling. Their strength is responsiveness: metabolomic profiles shift within days of a dietary or activity change, which makes them a plausible readout for whether something is doing anything.
Their weakness is the same property. A metabolomic age that moves with last night's dinner is not measuring a durable property, and separating a real trajectory from daily variation requires repeated sampling that few people will do.
A distinct and important strand is inflammatory ageing. Composite inflammatory signatures derived from large cohorts capture the chronic low-grade inflammatory drift often called inflammaging, and they predict frailty and mortality independently of chronological age. These connect directly to Pillar 3 territory and to markers a person can already have measured.
The hallmarks framework maps onto these layers reasonably well, and multi-omic measurement is the closest current attempt to observe several hallmarks simultaneously in a living person.
What Composite Clocks Get Right and Wrong
Combining layers improves prediction. Composites of methylation, proteomic and clinical chemistry outperform any single layer for mortality and morbidity, which is unsurprising and worth stating.
Three problems come with them. Cost rises sharply, since a large proteomic panel plus a methylation array plus metabolomics is an order of magnitude more expensive than a standard blood panel. Interpretability falls, because a composite of three models is harder to reason about than any one of them. And standardisation is absent: different platforms measure different protein sets with different affinity reagents, and results do not transfer between them.
There is also a subtler issue. Adding layers improves statistical prediction without necessarily improving individual guidance, because the wide outcome distribution at any given value does not narrow much. Better prediction of who dies first in a cohort of 50,000 is not the same as better advice for one person.
Availability and Cost in Practice
Most of this is research infrastructure rather than a consumer product. A few services offer organ-age panels, generally at a price point well above epigenetic testing, and the panels differ enough that results are not comparable between providers.
Standard clinical chemistry already provides crude organ-specific signals at a fraction of the cost: liver enzymes, estimated glomerular filtration rate and cystatin C for kidney, apolipoprotein B and blood pressure for vasculature, HbA1c for metabolic handling, high-sensitivity CRP for inflammatory load. These are less refined than a proteomic organ clock and vastly more accessible, and for most people they will identify the same drifting system.
The reasonable position for now is that multi-omic ageing is the most promising direction in the field and is not yet a purchase most people should make. It is worth understanding because it will shape what the next generation of tests looks like.
Why Asynchrony Changes the Framing
A single biological age number implies that ageing is one process running at one speed. The organ-specific data say otherwise, and that has a consequence for how anyone should think about their own optimisation.
If one system is drifting and the rest are not, the general longevity protocol, the one that assumes everybody's ageing is the same problem, is spending most of its effort where it is not needed. A framework organised by biological system, which is what the Constellation Pillars are, matches the underlying biology more closely than a single composite score does.
That is the practical takeaway from multi-omics even before the tests are affordable: ask which system, not how old.
The AEONNN Perspective
Organ-specific ageing is close to AEONNN's structural premise. The ten Constellation Pillars exist because ageing is not one process at one speed, and the proteomic organ-clock literature is the clearest external evidence for that position.
The Innovation layer tracks this work at preprint stage, and the Evidence layer holds it short of clinical readiness: platform standardisation is absent, cost is high, and individual guidance has not been validated. AEONNN does not recommend a multi-omic panel purchase, and it does read standard clinical chemistry for the same organ-level signal at a fraction of the price.
The mapping runs across Pillar 10 and Pillar 4, with the inflammatory signature strand touching Pillar 3. Where a member has organ-age data, the Pillar Matrix can accommodate it directly, because the data are already organised the way the Matrix is.
Pillar Matrix mapping
Longevity and Biological Age, Metabolic and Cardiovascular Health
Database Matrix layers
- Innovation Layer (bioRxiv preprints, patent filings)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
What is multi-omic aging?
Measuring ageing across several molecular layers at once, including proteins, metabolites, transcripts and the microbiome, rather than relying on DNA methylation alone.
What is organ age?
An age estimate for a single organ, derived by grouping plasma proteins by the tissue that predominantly produces them and modelling each group against age.
Does everyone age at the same rate across organs?
No. Most people have at least one organ ageing notably faster than the rest, and which organ it is varies between individuals.
Are organ age tests available to consumers?
A few services offer them, generally well above the price of epigenetic testing, and results are not comparable between providers because platforms measure different protein sets.
Are metabolomic clocks better than epigenetic ones?
They are more responsive and less stable. Metabolite profiles shift within days, which is useful for state and poor for a durable estimate.
Do composite clocks predict better?
Yes, combining layers improves population-level prediction. It also raises cost, reduces interpretability and does not necessarily improve guidance for one individual.
What can I use instead right now?
Standard clinical chemistry gives crude organ-specific signals cheaply: liver enzymes, kidney filtration markers, apolipoprotein B, HbA1c and high-sensitivity CRP.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.